Abstract
Higher serum urate concentration is associated with decreased risk of Parkinson’s disease (PD) as well as slower disease progression, but its relationship with severity of PD remains unclear. This study investigated whether changes in serum urate concentration over 5 years were associated with disease progression assessed by MDS-UPDRS Part III score, Hoehn and Yahr stage, or DaTscan imaging. Average serum urate concentration was stable over time and change in serum urate concentration did not correlate with worsening of measures of PD progression. These results suggest that serum urate concentration is not a monitoring biomarker of PD progression in early stages.
Highlights
Parkinson’s disease (PD) is a neurodegenerative disease characterized by loss of dopaminergic nigrostriatal neurons and progressive motor and cognitive deficits
The possibility that urate may be a marker of disease severity has been suggested by cross-sectional analyses of PD patients linking lower serum urate levels to more advanced disease state assessed by Hoehn and Yahr (H & Y) stage or Unified Parkinson’s Disease
Baseline characteristics of PD and healthy control (HC) subjects were comparable for age, sex, body mass index (BMI), and serum urate (Table 1)
Summary
Parkinson’s disease (PD) is a neurodegenerative disease characterized by loss of dopaminergic nigrostriatal neurons and progressive motor and cognitive deficits. The possibility that urate may be a marker of disease severity has been suggested by cross-sectional analyses of PD patients linking lower serum urate levels to more advanced disease state assessed by Hoehn and Yahr (H & Y) stage or Unified Parkinson’s Disease. Analysis of longitudinal data is required to determine whether urate concentration changes in association with the progression and increasing severity of the disease. Our study aimed to correlate longitudinal changes in disease severity with longitudinal changes in serum urate concentration in a well-characterized cohort of PD patients to clarify whether urate may serve as a monitoring biomarker of PD stage as well as a predictive biomarker of PD risk and rate of progression
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
